Table 2.

Multivariable regression analyses with backward selection of covariates for COVID-19 outcomes by medication class from adult cases in the SECURE-IBD registry

Outcome	Adjusted OR [95% CI]	p value
Hospitalization
VDZ vs all other IBD therapiesa	0.87 [0.72, 1.06]	0.17
VDZ monotherapy vs anti-TNF monotherapyb	1.38 [1.001, 1.90]	0.049
Severe COVID-19
VDZ vs all other IBD therapiesc	0.95 [0.53, 1.73]	0.88
VDZ monotherapy vs anti-TNF monotherapyd	2.92 [0.98, 8.71]	0.055

Abbreviations: COVID-19 = coronavirus disease 2019; SECURE-IBD = Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease; VDZ = vedolizumab; TNF = tumor necrosis factor; OR = odds ratio.

Statistically significant associations are in bold.

^aAdjusted for age, sex, Asian and other race/ethnicity category [reference: non-Hispanic White], IBD type, active IBD (reference: remission; based on Physician Global Assessment [PGA]) and number of comorbid conditions [1, ≥2; reference: 0].

^bAdjusted for age and IBD activity, Asian and other race/ethnicity category and number of comorbid conditions.

^cAdjusted for age, IBD type, IBD activity and number of comorbid conditions.

^dAdjusted for age and number of comorbid conditions.